Final survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial

Cancer research · Nasopharyngeal carcinoma

With a median follow-up of 10.6 years in the intention‑to‑treat population, 10‑year progression‑free survival is 70.7% in the lobaplatin‑based therapy group vs. 71.9% in the cisplatin‑based therapy group

In nasopharyngeal carcinoma, cisplatin is known to be associated with poor treatment compliance and notable side effects. More effective and safer platinum drugs are needed for the treatment of patients with nasopharyngeal carcinoma. In 2021, our multicenter, randomized, phase 3 trial reported that lobaplatin and fluorouracil induction chemotherapy plus concurrent chemoradiotherapy resulted in non‑inferior survival and fewer toxic effects than did cisplatin‑based therapy in nasopharyngeal carcinoma. Data from the 10‑year survival analysis are updated here. With a median follow-up of 10.6 years in the intention‑to‑treat population, 10‑year progression‑free survival is 70.7% in the lobaplatin‑based therapy group vs. 71.9% in the cisplatin‑based therapy group.

The data suggest that lobaplatin‑based induction chemotherapy combined with concurrent chemoradiotherapy is a safe and effective alternative to cisplatin‑based therapy for locoregionally advanced nasopharyngeal carcinoma.

Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.

Original source

Related signals